| Name | Title | Contact Details |
|---|
Hospice Touch is a Downey, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
US Post Acute Care is a Management Services Organization providing value-added service to clinical practice groups specializing in the care of patients in the post-acute setting. An organization with a national footprint, US Post Acute Care provides a full array of management services including billing, recruiting, training, compliance, analytics, and practice development. US Post Acute Care structures its services offering both to serve the needs as well as leverage the capabilities of its clinicians: the physicians and advanced practitioners dedicated to improving the quality of care for their patients. US Post Acute Care has designed and launched a proprietary clinical excellence program called SmartPAC™, a comprehensive clinical program for post-acute care designed to enable practitioners to improve patient outcomes with better quality care. Please
Ramp Health is a company that provides comprehensive healthcare and safety services to employer, health plan, and government clients.
Sunrise Medical Canada Inc is a Concord, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.